Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

CAR T-cells for CLL: ibrutinib pre-treatment, T-cell quality and future predictions
We know that CAR T-cell therapy is effective in the treatment of chronic lymphocytic leukemia (CLL); however, a current limitation is the collection of high quality originator T-cells from patients. S... Author: VJHemOnc Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel methods to assess the effectiveness of chemotherapy in AML patients: MRD
It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with the knowledge of minimal residual disease, it is understood that ... Author: VJHemOnc Added: 02/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Current management of Ph-positive ALL
There was exciting new trial data for the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposi... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Older acute myeloid leukemia (AML) patients are not typically given intensive cytotoxic chemotherapy due to their fragility and comorbidities. Decitabine has previously been demonstrated to improve su... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Ruxolitinib plus decitabine in post-MPN AML
The outcomes of patients with post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) are poor, with no standard therapy. In this interview, Farhad Ravandi, MD, from the University of T... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts